Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Cencora Earnings: What To Look For From COR

May 04, 2026 at 23:11 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

COR Cover Image

Healthcare distributor Cencora (NYSE: COR) will be reporting results this Wednesday before market open. Here’s what you need to know.

Cencora missed analysts’ revenue expectations last quarter, reporting revenues of $85.93 billion, up 5.5% year on year. It was a mixed quarter for the company, with a narrow beat of analysts’ EPS estimates but a slight miss of analysts’ revenue estimates.

Is Cencora a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Cencora’s revenue to grow 8% year on year, slowing from the 10.3% increase it recorded in the same quarter last year.

The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Cencora has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at Cencora’s peers in the health insurance providers segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Centene delivered year-on-year revenue growth of 7.1%, beating analysts’ expectations by 6.2%, and Elevance Health reported revenues up 1.5%, topping estimates by 2.4%. Centene traded up 24.1% following the results while Elevance Health was also up 5.5%.

Read our full analysis of Centene’s results here and Elevance Health’s results here.

There has been positive sentiment among investors in the health insurance providers segment, with share prices up 5.7% on average over the last month. Cencora is down 5.2% during the same time and is heading into earnings with an average analyst price target of $402.92 (compared to the current share price of $304.30).

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article